Sitagliptin Phosphate Monohydrate CAS 654671-77-9 Purity >99.0% (HPLC) API Factory High Quality

Short Description:

Chemical Name: Sitagliptin Phosphate Monohydrate

CAS: 654671-77-9

Purity: >99.0% (HPLC on the dried basis)

Appearance: White to Off-White Crystalline Powder

For the treatment of type II diabetes mellitus

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Supply Sitagliptin Phosphate Monohydrate Related Intermediates:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3

Chemical Properties:

Chemical Name	Sitagliptin Phosphate Monohydrate
Synonyms	(R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate monohydrate
CAS Number	654671-77-9
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C16H20F6N5O6P
Molecular Weight	523.3240802
Melting Point	202.0~204.0℃
Water Solubility	Soluble in Water
Specific Rotation	-18.0°~-23.0° (C=1, Water)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Crystalline Powder
Identification by HPLC	The retention time of sample is concordant with reference standard
IR-Infrared Spectrum	The IR Absorption Spectrum of the sample shall be concordant with that of standard spectrum
Phosphate	Complies
Purity / Analysis Method	>99.0% (HPLC on the dried basis)
Water Content (K.F)	3.3%~4.4%
Residue on Ignition	≤0.20%
Sulphate	≤0.02%
Chloride	≤0.05%
Chiral Impurity	<0.50%
Related Substances
Single Impurity	<0.50%
Total Impurities	<1.0%
Ethyl Acetate	<0.50%
Heavy Metals	<20ppm
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9), a new drug for the treatment of type 2 diabetes. In August 2009, the drug was approved by the European Union as a first-line drug for the treatment of type 2 diabetes. Sitagliptin Phosphate is the first FDA-approved dipeptidyl peptidase-IV inhibitor to be used in the treatment of type 2 diabetes by far, under the trade name Januvia. Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) rapidly and effectively degrades GLP-1, GLP-1, which is the most effective stimulator of insulin production and secretion Therefore, inhibition of DPP-IV can enhance the role of endogenous GLP-1, thereby increasing blood insulin levels, thereby reducing and maintaining blood glucose levels in diabetic patients. At present, medicine has confirmed that DPP-IV inhibitor is a new type of anti-diabetic drug, and clinical results show that the drugs have a good hypoglycemic effect. Because GLP-1 plays a glucose-dependent role in promoting insulin production and secretion, common adverse reactions such as hypoglycemia and weight gain caused by the use of antidiabetic drugs do not occur.